Nectin-4 & TROP-2 ADC Pipeline — PatSnap Eureka
Nectin-4 & TROP-2 ADC Pipeline: Next-Generation Payload & Linker Approaches
Exatecan, PNU-159682, and site-specific conjugation are redefining the Nectin-4 and TROP-2 ADC landscape beyond enfortumab vedotin and sacituzumab govitecan. Explore the patent intelligence powering next-generation ADC R&D.
Nectin-4 and TROP-2: Why These Targets Lead ADC Innovation
Nectin-4 (PVRL4) is a Ca²⁺-independent immunoglobulin-like cell adhesion molecule with tumor-specific overexpression in bladder cancer, breast cancer, and pancreatic cancer. Pathological analysis of 2,394 tumor patients confirmed Nectin-4 broad expression across these malignancies, while normal adult tissue expression is limited to skin, sweat glands, esophagus, and certain glandular structures. The target mediates efficient antibody internalization via endocytosis, making it particularly amenable to ADC payloads requiring lysosomal processing. Research published via PubMed and patent filings tracked through PatSnap Analytics confirm the target's favorable therapeutic window.
TROP-2 (encoded by TACSTD2) is a transmembrane glycoprotein involved in calcium signal transduction, cell growth, adhesion, and migration, overexpressed in approximately 80% of triple-negative breast cancers (TNBC) and broadly across epithelial malignancies including lung and bladder cancers. TROP-2 membranous expression correlates with worse clinical outcomes. The FDA-approved sacituzumab govitecan employs a hydrolysable linker to SN-38 enabling both intracellular and extracellular payload release, producing a bystander killing effect—but this same mechanism drives dose-limiting toxicities that next-generation programs are engineered to address.
Both targets are now the subject of a concentrated wave of next-generation patent activity focused on swapping established payloads for novel cytotoxins—particularly exatecan and anthracycline derivatives—while simultaneously advancing linker architectures. Teams working in life sciences R&D can leverage PatSnap Eureka to map the full IP landscape across both programs.
Next-Generation Cytotoxin Strategies Across Both Programs
Retrieved patents reveal a systematic displacement of first-generation payloads with higher-potency analogs and mechanistically distinct alternatives, targeting resistance and improved therapeutic index.
Exatecan: The Dominant Next-Gen Nectin-4 Payload
Five active or pending patents from Institut Jean Paoli & Irene Calmettes (France) and Eli Lilly (US/WO/EP/TW) disclose Nectin-4 ADCs comprising exatecan—a synthetic camptothecin derivative with higher intrinsic potency than SN-38. One EP filing explicitly claims these ADCs "can be used to treat auristatin-resistant cancer, including cancer that is resistant to treatment with enfortumab vedotin," directly addressing acquired resistance to the approved agent.
Resistance to enfortumab vedotin addressedPNU-159682: A Mechanistically Distinct TROP-2 Payload
Merck Sharp & Dohme (MSD) has filed a patent covering anti-TROP2 ADCs comprising derivatives of PNU-159682, an anthracycline metabolite. This provides a mechanistically distinct payload class—RNA polymerase II inhibition and DNA intercalation versus topoisomerase I inhibition—potentially addressing cross-resistance to the govitecan class. The preferential binding strategy targets high-expressing TROP-2 cells to improve tumor selectivity over normal tissue.
Cross-resistance to SN-38 potentially addressedTriple-Payload ADC Architecture (Araris Biotech)
A 2026 WO filing from Araris Biotech discloses a triple-payload ADC incorporating: (1) a cell-permeable topoisomerase I inhibitor (camptothecin class), (2) a non-cell-permeable topoisomerase I inhibitor, and (3) an auristatin such as MMAE—all within one ADC linker structure. This combinatorial payload design aims to achieve mechanistic diversification and simultaneously exploit bystander and cell-autonomous cytotoxic pathways.
Preclinical · Nascent IP stageNAMPT, HDAC, and DNA Cross-Linking Payloads
Beyond camptothecin and anthracycline classes, retrieved results document NAMPT inhibitors (Novartis) demonstrating in vivo efficacy in xenograft models via metabolic disruption; CBI-PDD DNA cross-linking agents (Femtogenix) achieving low picomolar cytotoxicity across 11 human tumor cell lines with antitumor activity at 1 mg/kg; and HDAC inhibitor payloads (Alfasigma S.p.A.) targeting ErbB receptors for epigenetic disruption.
Orthogonal to topoisomerase/tubulin mechanismsADC Pipeline Signals: Patent Landscape Visualised
Derived from patent and literature records retrieved via PatSnap Eureka across Nectin-4 and TROP-2 ADC programs.
TROP-2 ADC Next-Gen Approaches by Category
Distribution of next-generation TROP-2 ADC patent filings by innovation category, showing linker-modified SN-38 as the largest focus area.
Payload Mechanism Classes: Approved vs. Next-Generation
Mechanistic positioning of next-generation ADC payloads relative to approved agents for Nectin-4 and TROP-2 programs.
Linker Engineering: The Primary Competitive Axis for TROP-2 ADCs
With SN-38 as a validated payload, next-generation TROP-2 ADC differentiation hinges on linker architecture. Retrieved patents reveal multiple orthogonal engineering approaches.
Monitor Linker IP Filings Across TROP-2 and Nectin-4
PatSnap Eureka tracks new patent filings in real time—set alerts for linker chemistry innovations.
Site-Specific Conjugation: The Engineering Foundation of Next-Gen ADCs
A consistent theme across the retrieved dataset is the transition from stochastic to site-specific conjugation, enabling control of both DAR and conjugation site for improved PK and therapeutic window.
Redwood Bioscience / Catalent: Aldehyde Tag Platform
Site-specifically engineered aldehyde tags on antibody backbones react with hydrazine-functionalized payloads to form stable C-C bonds, enabling precise control of both drug-to-antibody ratio (DAR) and conjugation site. This platform underpins the tandem-cleavage linker work and represents a validated commercial-stage site-specific conjugation approach. Tracked across the PatSnap platform alongside related ADC IP.
Stable C-C bond formationReductive Alkylation at Antibody N-Termini
ABL Bio (Korea) discloses reductive alkylation to conjugate drugs at antibody N-termini via amine bonds, showing improved plasma stability and wider therapeutic window versus thiol-conjugated ADCs. This approach offers a defined, reproducible conjugation site without requiring antibody re-engineering or genetic code expansion. Relevant for both Nectin-4 and TROP-2 antibody scaffolds.
Improved vs. thiol-conjugated ADCsNon-Canonical Amino Acids for Bioorthogonal Conjugation
Veraxa Biotech (JP patent) discloses site-specifically modified immunoglobulins bearing non-canonical amino acid residues at predefined positions, enabling bioorthogonal conjugation chemistry. This approach allows precise placement of the drug-linker at any desired position in the antibody sequence, potentially optimizing internalization and lysosomal processing efficiency for both Nectin-4 and TROP-2 targets. EPO filings confirm active European patent activity in this space.
Predefined conjugation positionDefined Drug-Linker Architectures for Nectin-4 ADCs
Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (China) has filed patents (CA, EP) covering site-specifically conjugated Nectin-4 ADCs with defined drug-linker architectures (drug-linkers C-1 and C-3 versus MC-VC-MMAE), demonstrating superior tumor-killing versus randomized MMAE-based comparators. This represents an integrated composition-of-matter and conjugation IP strategy for next-generation Nectin-4 ADCs. See the PatSnap customer case studies for pharma IP strategy examples.
Superior vs. randomized MMAE comparatorsCombination Approaches and Platform Extension Strategies
Retrieved results signal combination and platform extension strategies that could define the next competitive wave in Nectin-4 and TROP-2 ADC development.
Nectin-4 ADC + Anti-PD-1 Combination
A CN patent from Maiwei (Shanghai) Biosciences (2025) discloses a drug combination comprising an anti-Nectin-4 ADC and an anti-PD-1 antibody, claiming synergistic tumor suppression and improved safety versus monotherapy. Retrieved text notes "the drug combination exhibits synergistic tumor-inhibitory effects," signaling that Chinese developers are pursuing chemo-immuno combination approaches with Nectin-4 ADCs as anchor agents.
Hypoxia-Responsive Stimuli-Responsive Linkers
A 2022 paper from the Beijing Institute of Pharmacology and Toxicology describes a "pro-prodrug" ADC concept using nitroaromatic-containing linkers activated by nitroreductase (NTR) specifically in hypoxic tumor tissue (O₂ < 1%), remaining stable in normal tissue (O₂ > 10%). This tumor-microenvironment-responsive release mechanism is not yet applied to Nectin-4 or TROP-2 specifically in the retrieved dataset, but signals an emerging direction for both targets.
Assignee Landscape: Who Is Filing Next-Gen ADC Patents?
Among retrieved results, patent activity is heavily weighted toward commercial assignees, while academic literature provides primarily platform-level linker and payload chemistry insights. Chinese-origin companies constitute the single largest national cluster of Nectin-4 and TROP-2 ADC patent filers in this dataset—particularly Jiangsu Mabwell, Maiwei (Shanghai), Levena (Suzhou), and Escugen (Shanghai). Their filings cover both composition-of-matter (antibody sequences, site-specific conjugation) and formulation patents, suggesting integrated IP coverage strategies.
For Nectin-4, Institut Jean Paoli & Irene Calmettes (France) appears to be the originating institution for the Nectin-4 + exatecan payload–target combination, with 3–4 active/pending US and EP filings. Eli Lilly and Company (US) holds 2 pending filings (US, WO) covering the same invention, indicating a licensing or co-development relationship. Aix-Marseille University is co-inventor on the TW filing. Monitoring WIPO PCT filings is critical to tracking international extension of these positions.
For TROP-2, Levena (Suzhou) Biopharma leads with 2 IL-pending filings on anti-TROP2 + SN-38 ADCs with modified linkers. Merck Sharp & Dohme LLC holds a strategically significant AU-pending position on PNU-159682 anthracycline derivative payloads. OBI Pharma (Taiwan) and Chen Ya-Chi hold WO/AU filings on improved linker-payload conjugates with bioorthogonal and hydrophilic elements applicable to TROP-2, HER2, and Nectin-4. Western pharma and biotech teams should use PatSnap's IP analytics to monitor CN-originating patents for PCT/international extension filings.
Platform and linker chemistry contributions come from academic and mixed-sector sources: Novartis Institutes for BioMedical Research (NAMPT inhibitor payload), Femtogenix (CBI-PDD DNA cross-linking), Catalent Pharma Solutions (tandem-cleavage linker), Genentech (linker PK/efficacy studies), Abzena Ltd. (hydrophilic macrocycle drug-linker reagents), and Centre de Recherche en Cancérologie de Lyon (polysarcosine high-loading platform). The full IP landscape is searchable via PatSnap's open data API.
What the Patent Signals Mean for ADC Drug Developers
Key strategic takeaways derived from the retrieved patent and literature dataset for teams entering or monitoring the Nectin-4 and TROP-2 ADC space.
Exatecan IP Blocking Strategy Requires FTO Assessment
The convergence of Institut Jean Paoli/Eli Lilly and Aix-Marseille University patents around Nectin-4 + exatecan—explicitly positioned to overcome enfortumab vedotin resistance—signals a clear IP blocking strategy. Drug developers entering the Nectin-4 space should evaluate freedom-to-operate around exatecan-linker-antibody combinations, particularly in US, EP, WO, and TW jurisdictions where these filings are active or pending.
US · EP · WO · TW jurisdictions at riskLinker IP—Not Antibody or Payload—Is the Key TROP-2 Differentiator
With SN-38 as a validated payload, the next competitive dimension for TROP-2 ADCs is linker engineering to improve the stability/release balance. Both the Levena/Escugen filings and the OBI Pharma bioorthogonal hydrophilic linker patent indicate that linker IP—not antibody or payload IP—may be the key differentiation point for second-generation TROP-2 ADCs.
Linker IP as primary moatMSD's PNU-159682 Represents a Mechanistically Distinct Non-SN-38 Path
MSD's AU filing on PNU-159682-bearing TROP-2 ADCs with preferential high-expressor binding may address both topoisomerase resistance and therapeutic index limitations of the govitecan class. This is a strategically significant alternative payload IP position by a major pharma player that could redefine the TROP-2 competitive landscape if clinical proof-of-concept emerges.
Major pharma alternative payload positionMulti-Payload and Stimuli-Responsive Linkers: Pre-Clinical But Directionally Significant
The Araris triple-payload ADC and hypoxia-sensitive nitroaromatic linker concepts represent pre-clinical platform signals that, if validated, could enable next-generation ADC designs for both Nectin-4 and TROP-2 that transcend single-payload limitations. Early IP positions in these platform technologies may carry disproportionate value if clinical proof-of-concept emerges.
Early positions may carry outsized valueNectin-4 & TROP-2 ADC Pipeline — key questions answered
All retrieved Nectin-4 ADC patents position exatecan as the replacement payload for MMAE/auristatin, specifically to address enfortumab vedotin resistance. Institut Jean Paoli & Irene Calmettes and Eli Lilly and Company have filed patents explicitly claiming that exatecan-based Nectin-4 ADCs can treat auristatin-resistant cancer, including cancer resistant to enfortumab vedotin.
With SN-38 as a validated payload, the next competitive dimension for TROP-2 ADCs is linker engineering to improve the stability/release balance. The hydrolysable CL2A linker in sacituzumab govitecan enables bystander killing via membrane-permeable SN-38 but is simultaneously its mechanistic strength and clinical liability. Next-generation filings are explicitly engineered to modulate this release kinetics to reduce dose-limiting gastrointestinal and hematologic toxicities.
PNU-159682 is an anthracycline metabolite payload being developed by Merck Sharp & Dohme (MSD) in an anti-TROP2 ADC. It provides a mechanistically distinct payload class—RNA polymerase II inhibition and DNA intercalation—versus topoisomerase I inhibition used by SN-38, potentially addressing cross-resistance to the govitecan class and offering improved tumor selectivity through preferential binding to high-expressing TROP-2 cells.
Chinese-origin companies constitute the single largest national cluster of Nectin-4 and TROP-2 ADC patent filers in this dataset, particularly Jiangsu Mabwell, Maiwei (Shanghai), Levena (Suzhou), and Escugen (Shanghai). Their filings cover both composition-of-matter and formulation patents. Institut Jean Paoli & Irene Calmettes (France) and Eli Lilly (US) lead the Nectin-4 exatecan IP position, while Merck Sharp & Dohme holds a strategic TROP-2 anthracycline payload position.
Site-specific conjugation is the transition from stochastic to defined attachment of drug payloads to antibodies, enabling control of both drug-to-antibody ratio (DAR) and conjugation site. Approaches include aldehyde tag/HIPS chemistry, N-terminal selective reductive alkylation, genetic code expansion with non-canonical amino acids, and bioorthogonal linker-payload conjugates with hydrophilic moieties. These methods improve plasma stability, reduce aggregation, and widen the therapeutic window compared to thiol-conjugated ADCs.
The Araris Biotech WO filing (2026) describes a linker accommodating three distinct payloads simultaneously: a cell-permeable topoisomerase I inhibitor (camptothecin class), a non-cell-permeable topoisomerase I inhibitor, and an auristatin such as MMAE—all within one ADC linker structure. This combinatorial payload design aims to achieve mechanistic diversification and simultaneously exploit bystander and cell-autonomous cytotoxic pathways. Retrieved text does not report in vivo data but signals structural feasibility of multi-payload linker engineering.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your ADC QuestionsMap the Full Nectin-4 and TROP-2 ADC IP Landscape
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search exatecan, PNU-159682, linker architectures, and site-specific conjugation patents in real time.
References
- Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload — Institut Jean Paoli & Irene Calmettes, 2025, US [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Eli Lilly and Company, 2026, US [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Institut Jean Paoli & Irene Calmettes, 2025, US [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Institut Jean Paoli & Irene Calmettes, 2025, EP [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Institut Jean Paoli & Irene Calmettes, 2025, EP [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Eli Lilly and Company, 2025, WO [Patent]
- Antibody drug conjugate (ADC) targeting nectin 4 and comprising an exatecan payload — Aix-Marseille University, 2025, TW [Patent]
- Antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody — Levena (Suzhou) Biopharma Co., Ltd., 2022, IL [Patent]
- Antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody — Levena (Suzhou) Biopharma Co., Ltd., 2023, IL [Patent]
- Antibody-drug conjugates (ADCs) containing anti-TROP2 antibodies — Shanghai Escugen Biotechnology Co., Ltd., 2023, JP [Patent]
- Anti-trop2 antibody-drug conjugates comprising PNU-159682 derivatives — Merck Sharp & Dohme LLC, 2025, AU [Patent]
- Anti-trop2 antibody-drug conjugate — Sapporo Medical University, 2018, EP [Patent]
- Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof — Chen Ya-Chi, 2025, WO [Patent]
- Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof — OBI Pharma, Inc., 2025, AU [Patent]
- Anti-Nectin-4 antibody drug conjugate and anti-PD-1 antibody drug combination and use thereof — Maiwei (Shanghai) Biosciences Co., Ltd., 2025, CN [Patent]
- Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates — Novartis Institutes for BioMedical Research, 2018 [Paper]
- DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies — Femtogenix, 2022 [Paper]
- Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates — Beijing Institute of Pharmacology and Toxicology, 2021 [Paper]
- WIPO — World Intellectual Property Organization — International PCT patent filings database
- EPO — European Patent Office — European patent register and search
- FDA — U.S. Food & Drug Administration — Sacituzumab govitecan and enfortumab vedotin approval data
- PubMed — National Library of Medicine — Clinical literature on TROP-2 and Nectin-4 expression and ADC trials
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.